Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy.

Cancer research - 1 Aug 2004

Lu Yingnian, Bellgrau Donald, Dwyer-Nield Lori D, Malkinson Alvin M, Duke Richard C, Rodell Timothy C, Franzusoff Alex

Abstract excerpt

Activating mutations in Ras oncoproteins represent attractive targets for cancer immunotherapy, but few vectors capable of generating immune responses required for tumor killing without vector neutralization have been described. Whole recombinant yeast heterologously expressing mammalian mutant Ras proteins were used to immunize mice in a carcinogen-induced lung tumor model. Therapeutic immunization with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoma
Share to DNA, Neoplasm
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred Strains

Share to Neoplasms, Experimental

Share to Proto-Oncogene Proteins p21(ras)

Share to Recombinant Proteins

Share to Urethane

Source

Identifiers

PMID: 15289309
DOI: 10.1158/0008-5472.CAN-04-1487

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy.PMID 15289309Read ↗

Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.Semantic proximity Read ↗

Human cancer-targeted immunity via transgenic hematopoietic stem cell progenySemantic proximity Read ↗

Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.Semantic proximity Read ↗

Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.Semantic proximity Read ↗

Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes.Semantic proximity Read ↗

Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeastSemantic proximity Read ↗

Rapid generation of potent antibodies by autonomous hypermutation in yeastSemantic proximity Read ↗

Shuffled antibody libraries created by in vivo homologous recombination and yeast surface displaySemantic proximity Read ↗

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.Semantic proximity Read ↗

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.